S
Sally F. Barrington
Researcher at King's College London
Publications - 223
Citations - 16210
Sally F. Barrington is an academic researcher from King's College London. The author has contributed to research in topics: Positron emission tomography & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 12689 citations. Previous affiliations of Sally F. Barrington include Canterbury Hospital & King's College.
Papers
More filters
Journal ArticleDOI
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson,Richard I. Fisher,Sally F. Barrington,Franco Cavalli,Lawrence H. Schwartz,Emanuele Zucca,T. Andrew Lister +6 more
TL;DR: Recommendations to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma and non-Hodgkin lymphomas and enhance the ability to compare outcomes of clinical trials are made.
Journal ArticleDOI
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard,Roberto Delgado-Bolton,Wim J.G. Oyen,Francesco Giammarile,Klaus Tatsch,W. Eschner,Fred J. Verzijlbergen,Sally F. Barrington,Lucy Pike,Wolfgang A. Weber,Sigrid Stroobants,Dominique Delbeke,Kevin J. Donohoe,Scott Holbrook,Michael M. Graham,Giorgio Testanera,Otto S. Hoekstra,Josée M. Zijlstra,Eric P. Visser,Corneline J. Hoekstra,Jan Pruim,Antoon T.M. Willemsen,Bertjan Arends,Joerg Kotzerke,Andreas Bockisch,Thomas Beyer,Arturo Chiti,Bernd J. Krause +27 more
TL;DR: Both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
Imaging biomarker roadmap for cancer studies.
James P B O'Connor,Eric O. Aboagye,Judith E. Adams,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Sally F. Barrington,Ambros J. Beer,Ronald Boellaard,Sarah E. Bohndiek,J. Michael Brady,Gina Brown,David L. Buckley,Thomas L. Chenevert,Laurence P. Clarke,Sandra Collette,Gary Cook,Nandita M. deSouza,John Dickson,Caroline Dive,Jeffrey L. Evelhoch,Corinne Faivre-Finn,Ferdia A. Gallagher,Fiona J. Gilbert,Robert J. Gillies,Vicky Goh,John R. Griffiths,Ashley M. Groves,Steve Halligan,Adrian L. Harris,David J. Hawkes,Otto S. Hoekstra,Erich P. Huang,Brian Hutton,Edward F. Jackson,Gordon C Jayson,Andrew J. I. Jones,Dow-Mu Koh,Denis Lacombe,Philippe Lambin,Nathalie Lassau,Martin O. Leach,Ting-Yim Lee,Edward Leen,Jason S. Lewis,Yan Liu,Mark F. Lythgoe,Prakash Manoharan,Ross J. Maxwell,Kenneth A. Miles,Bruno Morgan,Steve Morris,Tony Ng,Anwar R. Padhani,Geoff J M Parker,Mike Partridge,Arvind P. Pathak,Arvind P. Pathak,Andrew C. Peet,Shonit Punwani,Andrew R. Reynolds,Simon P. Robinson,Lalitha K. Shankar,Ricky A. Sharma,Dmitry Soloviev,Sigrid Stroobants,Daniel C. Sullivan,Stuart A. Taylor,Paul S. Tofts,Gillian M. Tozer,Marcel van Herk,Simon Walker-Samuel,James Wason,Kaye J. Williams,Paul Workman,Thomas E. Yankeelov,Kevin M. Brindle,Lisa M. McShane,Alan Jackson,John C. Waterton +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
Journal ArticleDOI
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.